Application of depsidone compound in preparation of neuroprotective drugs

A technology of depsipphenolic acid cyclic ether and neuroprotection, which is applied in the field of biochemical medicine and can solve the problems of high toxicity and side effects and high price

Pending Publication Date: 2019-12-13
GUANGDONG OCEAN UNIVERSITY +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The technical problem to be solved by the present invention is to overcome the disadvantages of the existing drugs for treating neurodegenerative diseases, such as large toxic and side effects and high price, and at the same time make up for the gap in neuroprotection of depsipphenolic acid cyclic ether compounds, and provide depsipphenolic acid cyclic ethers Application of compound in preparation of neuroprotective medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of depsidone compound in preparation of neuroprotective drugs
  • Application of depsidone compound in preparation of neuroprotective drugs
  • Application of depsidone compound in preparation of neuroprotective drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] The preparation of embodiment 1 depsipphenolic acid cyclic ether compound

[0055] The preparation method of depsipphenolic acid cyclic ether compound comprises the following steps:

[0056] S1. Fermentation: inoculate the marine fungus Aspergillus unguis 6-20-6 in the fungal liquid culture medium and leave it to ferment for 21 days, filter, and collect the mycelia and fermentation broth respectively;

[0057] Wherein, the formula of the fungal liquid medium in step S1 is: 500 mL of fresh potato juice, 20 g of sea salt, 20 g of sucrose, 5.5 g of peptone, 500 mL of distilled water, and pH 7.

[0058] S2. Rough extraction: the fermentation broth obtained in step S1 is ultrasonically extracted 3 times with ethyl acetate and concentrated, and the mycelium obtained in step S1 is ultrasonically extracted 3 times with a mixed solvent of acetone and methanol and concentrated under reduced pressure, and the resulting concentration is The things are combined to obtain the crude ...

Embodiment 2

[0066] The determination of the neuroprotective activity of embodiment 2 depsipphenolic acid cyclic ether compounds

[0067] 1. Experimental method

[0068] After anesthetizing the pregnant mouse (ICR) at embryonic day 14 (E14), take out the embryo, separate the cerebral cortex, remove the outer dura mater, cut up the tissue, and separate the cerebral cortex nerve cells through trypsinization and other processes, suspend in the containing In 12% horse serum, 0.6% D-glucose and 2mM L-glutamine in neural basal medium (GibcoBRL), the neural cells were seeded in 96-well plates pretreated with 5 μg / mL poly-D-lysine (Sigma) , 37°C, 5% CO 2 Cultured under the condition of 20000 cells per well, the culture medium was replaced with 2% B-27 neural basal medium (Gibco BRL) after 3-12 hours.

[0069] Then, after the nerve cells were cultured in the B-27 medium for 4 days, different concentrations (1 μM, 10 μM) of the depsipaldehyde cyclic ether compounds Aspergillusidone A (group A1, gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a depsidone compound in preparation of neuroprotective drugs. The depsidone compound is proved to significantly improve the survival rate of cerebral cortex nerve cells, and has an extremely significant reversal effect on MPP+ induced cerebral cortex nerve cell damage; in addition, the depsidone compound is efficient and free of toxic and side effects on patients. Therefore, the depsidone compound can be applied to preparation of the neuroprotective drugs, preparation of drugs for relieving/reversing MPP+ induced nerve cell damage and preparation of drugs for preventing/treating neurodegenerative diseases. A new technology, a new method and a new means are provided for efficiently treating neurodegenerative diseases, especially Parkinson's disease,and a good application prospect and a wide development space are achieved.

Description

technical field [0001] The invention belongs to the technical field of biochemical medicine. More specifically, it relates to the application of depsipphenolic acid cyclic ether compounds in the preparation of neuroprotective drugs. Background technique [0002] Neurodegenerative diseases refer to a class of chronic, progressive neurological diseases that cause impairment of memory, mobility and consciousness due to the loss of neurons in the brain and spinal cord. With the aging of the population and the deterioration of the environment, the threat of neurodegenerative diseases to humans is becoming more and more serious; among them, Alzheimer's disease (Alzheimer's disease, AD) and Parkinson's disease (Parkinson's disease, PD) are the most influential ). [0003] PD seriously threatens the physical and mental health of the elderly. The current research results show that its main pathological features are the degeneration of dopaminergic neurons in the substantia nigra pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P25/00A61P25/16
CPCA61K31/365A61P25/00A61P25/16
Inventor 张翼杨文聪聂影影杨志友刘亚月宋采洪鹏志
Owner GUANGDONG OCEAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap